In January 2006, the U.S. Food and Drug Administration (FDA) approved a new antianginal agent for the treatment of chronic stable angina, ranolazine (Ranexa™; CV Therapeutics, Inc.). The drug, ...

Angina pectoris, often shortened to angina, is chest pain or discomfort caused by reduced blood flow to the heart. It is most ...

A drug used in the clinical treatment of angina symptoms also has an anti-inflammatory effect and reduces atherosclerotic plaques in blood vessels - thereby reducing the risk of heart attack or stroke ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window As a second test ...

When a robust man suddenly drops dead and the newspapers report “heart failure,” the probability is that he died during an attack of angina pectoris. If he had gone to his doctor the day before, the ...

THE earliest description of angina pectoris, that of Heberden 1 in 1786, refers to "the relief afforded by wine and spirituous cordials." Since then alcoholic beverages have frequently been ...

The diagnosed prevalent cases of angina pectoris is expected to increase from 19.58 million cases in 2018 to 22.79 million cases in 2028, at an annual growth rate (AGR) of 1.64% across the seven major ...

Most patients with coronary artery disease (CAD) and chronic stable angina will obtain complete relief of symptoms with percutaneous coronary intervention (PCI). However, some chronic angina patients ...